MedPath

Tezspire Shows Promise in Phase III Trial for Nasal Polyps

• AstraZeneca and Amgen's Tezspire demonstrated a reduction in nasal polyp size and improved nasal congestion in a Phase III trial. • The anti-TSLP agent, already approved for severe asthma, may be a potential new treatment option for nasal polyps. • Positive results could lead to a second indication for Tezspire, expanding its therapeutic application. • AstraZeneca and Amgen are planning to file Tezspire for nasal polyps based on the Phase III trial data.

AstraZeneca and Amgen's Tezspire, a first-in-class anti-thymic stromal lymphopoietin (TSLP) agent, has exhibited promising results in a Phase III trial for the treatment of nasal polyps. The study demonstrated that Tezspire significantly reduced the size of nasal polyps and improved nasal congestion in patients. These findings suggest that Tezspire, already approved for severe asthma, could potentially become a valuable treatment option for individuals suffering from nasal polyps.
The positive outcome of this Phase III trial may pave the way for a second indication for Tezspire. AstraZeneca and Amgen are planning to file Tezspire for nasal polyps based on the Phase III readout. If approved, this would broaden the therapeutic application of Tezspire and offer a new treatment avenue for patients with this condition.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Tezepelumab Shows Promise in Phase III Trial for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca's Tezspire (tezepelumab) significantly reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the Phase III WAYPOINT trial.
The WAYPOINT trial evaluated tezepelumab versus placebo in adults with severe CRSwNP who remained symptomatic despite standard intranasal corticosteroid treatment.

Tezspire Demonstrates Positive Results in Phase 3 Trial for Chronic Rhinosinusitis with Nasal Polyps

Tezspire (tezepelumab) met the co-primary endpoints in the WAYPOINT trial, showing significant reduction in nasal polyp size compared to placebo.
The trial demonstrated that Tezspire also significantly reduced nasal congestion in adult patients with severe CRSwNP.

Tezspire Meets Co-Primary Endpoints in Phase III WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

Tezspire (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size compared to placebo in the Phase III WAYPOINT trial.
The WAYPOINT trial also showed that Tezspire significantly reduced nasal congestion in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP).

Tezspire Meets Primary Endpoints in WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca and Amgen's Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size compared to placebo in the Phase III WAYPOINT trial.
The trial evaluated Tezspire in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who remained symptomatic despite standard intranasal corticosteroid treatment.

Tezspire Demonstrates Significant Improvement in Chronic Rhinosinusitis with Nasal Polyps in Phase III Trial

Tezspire (tezepelumab) significantly reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.
The Phase III trial assessed Tezspire's efficacy and safety in adults with persistent symptoms despite standard intranasal corticosteroid treatment.

Tezspire Demonstrates Success in Phase III Nasal Polyps Trial

AstraZeneca and Amgen's Tezspire met the co-primary endpoints in a Phase III trial for chronic rhinosinusitis with nasal polyps (CRSwNP).
The WAYPOINT study showed a statistically significant and clinically meaningful reduction in nasal polyp size and nasal congestion compared to placebo.

Tezspire Demonstrates Significant Reduction in Nasal Polyp Size and Congestion in Phase III WAYPOINT Trial

AstraZeneca and Amgen's Tezspire met co-primary endpoints in the Phase III WAYPOINT trial, showing a statistically significant reduction in nasal polyp size.
The trial demonstrated a clinically meaningful reduction in nasal congestion in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.

Tezspire Demonstrates Significant Improvement in Nasal Polyp Symptoms in Phase III Trial

AstraZeneca's Tezspire significantly reduced nasal polyp size and congestion in patients with severe chronic rhinosinusitis with nasal polyps in the Phase III WAYPOINT trial.
The trial results suggest Tezspire could decrease the need for surgery and corticosteroids, offering a new treatment approach for this chronic condition.

Tezspire Meets Primary Endpoints in Phase 3 WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

Tezspire (tezepelumab-ekko) demonstrated a statistically significant reduction in nasal polyp size compared to placebo in the Phase 3 WAYPOINT trial.
The trial also showed a clinically meaningful reduction in nasal congestion for patients treated with Tezspire versus those receiving placebo.

Tezspire Meets Primary Endpoints in Phase III WAYPOINT Trial for Nasal Polyps

AstraZeneca and Amgen's Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size compared to placebo in the WAYPOINT trial.
The trial also showed a significant reduction in nasal congestion for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Tezspire.

Reference News

[1]
Tezspire Phase III Nasal Polyp Data May Lead To Second Indication - Citeline
insights.citeline.com · Nov 9, 2024

AstraZeneca and Amgen's Tezspire, approved for severe asthma, showed reduction in nasal polyp size and improved congesti...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy